RECRUITING · INTERVENTIONAL · TREATMENT study · Relapsed Advanced Lymphomas · Phase 1 · Enrollment 40 · Sponsor: Aurigene Discovery Technologies Limited
Official title: A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 In Patients With Relapsed Advanced Lymphoma (ADITI-1)
Summary: A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
Conditions: Relapsed Advanced Lymphomas
Keywords: Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Relapse Advanced Lymphomas
Study type: INTERVENTIONAL
Primary purpose: TREATMENT
Phases: PHASE1
Enrollment: 40 (ESTIMATED)
Status: RECRUITING
Completion: 2028-01-15 (ESTIMATED)